ABOUT US
GROUND-BREAKING THERAPEUTICS

Scroll down to see more

About Laekna


Founded in 2016, Laekna is a clinical-stage global biotechnology company, dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide.


The company has two potential core products: LAE002 is an investigational highly selective adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The other Core Product LAE001 is an investigational potential first-in-class next-generation androgen synthesis inhibitor that simultaneously inhibits both CYP17A1 and CYP11B2 for the treatment of prostate cancer.


Laekna’s robust infrastructure has already enabled the rapid development of 14 innovative product candidates, including one pivotal clinical trial and another five clinical trials for our potential Core Products. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address urgent yet unmet global medical needs in the standard of care (SOC)-resistant cancers.


Laekna’s internal drug discovery primarily focuses on coordinating the human immune system to treat cancer and liver fibrosis.



Our Vision
Our Vision

We are committed to
becoming a globally leading innovative
biopharmaceutical
company
that can bring ground-breaking therapies
to cancer and liver fibrosis
patients worldwide.

Core Management Team
Milestones
2016

Laekna establised

2017

In June, we acquired global licenses of LAE001 from Novartis

2018

In January, we completed onshore Series Seed financing

 

In May, we completed Series A financing

 

In May, we acquired global licenses of LAE002 and LAE003 from Novartis

2019

In January, we received IND approval for Phase I/II clinical trial of LAE001 for mCRPC from NMPA in China

 

In May, we received IND approval for Phase I LAE002 and LAE001 combination MRCT study in patients with mCRPC from FDA in the United States

 

In November, we received IND approval for pivotal Phase II MRCT study of LAE002 plus paclitaxel versus paclitaxel in patients with PROC from FDA in the United States

2020

In February, we completed Series B financing

 

In February, we acquired global license of LAE005 from Novartis

 

In August, we received IND approval for pivotal Phase II MRCT study of LAE002 plus paclitaxel versus paclitaxel in patients with PROC from NMPA in China

 

In December, we received IND approval for Phase I/II clinical trial of LAE002 combined with LAE005 and nab-paclitaxel for TNBC from NMPA in China

2021

In February, we completed Phase I LAE002 and LAE001 combination study in patients with mCRPC in the United States, and entered Phase II stage

 

In March, we completed Series C financing

 

In May, we declared the first internally discovered pre-clinical candidate, ActRIIA antibody for immunotherapy of cancers and advanced it to IND-enabling studies

 

In June, we received IND approval for Phase Ib/III study of LAE002 plus fulvestrant in patients with locally advanced or metastatic HR+/HER2- breast cancer from FDA in the United States

 

In July, we entered into a collaboration agreement with Innovent to develop a combination therapy of LAE002 with sintilimab, targeting patients with solid tumors with prior PD-1/PD-L1 treatments

 

In August, we received IND approval for Phase Ib/III study of LAE002 plus fulvestrant in patients with locally advanced or metastatic HR+/HER2- breast cancer from NMPA in China

 

In September, we completed Phase I clinical trial of LAE001 for mCRPC in China, and entered Phase II stage

2022

In January, we received IND approval for Phase I/II combination therapy of LAE002 with sintilimab, targeting patients with solid tumors with prior PD-1/PD-L1 treatments from NMPA in China

 

In March, we received IND approval for Phase II LAE002 and LAE001 combination study in patients with mCRPC in South Korea

 

In April, we completed Series D financing

Lab at Zhangjiang Hi-Tech Park

Glossary & abbreviations

MCRPC: metastatic castration-resistant prostate cancer IND: investigational new drug MRCT: multi-regional clinical trial PROC: platinum-resistant ovarian cancer TNBC: triple negative breast cancer ActRIIA: activin receptor type IIA HR+/HER2- breast cancer: the most common type of breast cancer with overexpression of HR and without overexpression of HER2
Honors & Awards
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin